Zevra Therapeutics price target raised to $25 from $18 at Maxim

Maxim raised the firm’s price target on Zevra Therapeutics to $25 from $18 and keeps a Buy rating on the shares. The firm cites the FDA having announced the approval of Miplyffa, or arimoclomol, in combination with miglustat for the treatment of neurological manifestations of Niemann-Pick disease type C, representing the first U.S. approval for the disease, the analyst tells investors in a research note. Though a small population with about 900 patients in the U.S., the expectation is that this could be a $1B+ market opportunity for Zevra with initial pricing expected to be about $1M on average per patient, the firm added.